Rep protein as protein antigen for use in diagnostic assays
US-2024018223-A1 · Jan 18, 2024 · US
Cell with surface coated with ANXA1 and use thereof
US9470677B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9470677-B2 |
| Application number | US-201414554955-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 26, 2014 |
| Priority date | Nov 28, 2013 |
| Publication date | Oct 18, 2016 |
| Grant date | Oct 18, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A cell having a surface coated with Annexin A1 (ANXA1), a method of detecting a substance binding to ANXA1 using the cell, and a method of preparing the cell are provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for screening for an ANXA1 binding substance that binds to ANXA1 on a surface of a cancer cell, the method comprising providing the cancer cell having a surface coated with ANXA1, wherein the ANXA1 is exogenous to the cancer cell; contacting the cancer cell with a candidate substance, measuring a reaction between ANXA1 and the candidate substance, and selecting the candidate substance as the ANXA1 binding substance that binds to ANXA1 on the surface of the cancer cell, when the reaction between ANXA1 and the candidate substance is confirmed, wherein the cancer cell is a triple-negative breast cancer cell line, SNU-1, MCF7, HCT116, or a combination thereof. 2. The method of claim 1 , wherein the candidate substance is at least one selected from the group consisting of nucleic acids, peptides, proteins, synthetic compounds, cultures of microorganisms, natural ingredients obtained from plants or animals, plant extracts, animal tissue extracts, and any combination thereof. 3. The method of claim 1 , wherein the ANXA1 is a human ANXA1.
Assignees
Inventors
Classifications
involving cells · CPC title
- G01N33/502Primary
for testing non-proliferative effects · CPC title
Assays involving receptors, cell surface antigens or cell surface determinants · CPC title
Modification of the membrane of cells, e.g. cell decoration · CPC title
Proteins not provided for elsewhere · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9470677B2 cover?
- A cell having a surface coated with Annexin A1 (ANXA1), a method of detecting a substance binding to ANXA1 using the cell, and a method of preparing the cell are provided.
- Who is the assignee on this patent?
- Samsung Electronics Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification G01N33/502. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).